Literature DB >> 9733819

Serp2, an inhibitor of the interleukin-1beta-converting enzyme, is critical in the pathobiology of myxoma virus.

F Messud-Petit1, J Gelfi, M Delverdier, M F Amardeilh, R Py, G Sutter, S Bertagnoli.   

Abstract

Recently, myxoma virus was shown to encode an additional member of the serpin superfamily. The viral gene, called serp2, was cloned, and the Serp2 protein was shown to specifically bind to interleukin-1beta (IL-1beta)-converting enzyme (ICE), thus inhibiting the cleavage of pro-IL-1beta by the protease (F. Petit, S. Bertagnoli, J. Gelfi, F. Fassy, C. Boucraut-Baralon, and A. Milon, J. Virol. 70:5860-5866, 1996). Here, we address the role of Serp2 in the development of myxomatosis, a lethal infectious disease of the European rabbit. A Serp2 mutant myxoma virus was constructed by disruption of the single-copy serp2 gene and insertion of the Escherichia coli gpt gene serving as the selectable marker. A revertant virus was obtained by replacing the E. coli gpt gene by the intact serp2 open reading frame. The Serp2(-) mutant virus replicated with wild-type kinetics both in rabbit fibroblasts and a rabbit CD4(+) T-cell line (RL5). Moderate reduction of cell surface levels of major histocompatibility complex I was observed after infection with wild-type or Serp2(-) mutant myxoma virus, and both produced white pocks on the chorioallantoic membrane of the chick embryo. After the infection of European rabbits, the Serp2(-) mutant virus proved to be highly attenuated compared to wild-type myxoma virus, as demonstrated by the clinical course of myxomatosis and the survival rates of infected animals. Pathohistological examinations revealed that infection with wild-type myxoma virus resulted in a blockade of the inflammatory response at the vascular level. In contrast, rapid inflammatory reactions occurred upon infection with the Serp2(-) mutant virus. Furthermore, lymphocytes in lymph nodes derived from animals inoculated with Serp2 mutant virus were shown to rapidly undergo apoptosis. We postulate that the virulence of myxoma virus in the European rabbit can be partially attributed to an impairment of host inflammatory processes and to the prevention of apoptosis in lymphocytes. The weakening of host defense is directly linked to serp2 gene function and is likely to involve the inhibition of IL-1beta-converting-enzyme-dependent pathways.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733819      PMCID: PMC110100     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Acute inflammatory response to cowpox virus infection of the chorioallantoic membrane of the chick embryo.

Authors:  T N Fredrickson; J M Sechler; G J Palumbo; J Albert; L H Khairallah; R M Buller
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

2.  Cloning of a new cytokine that induces IFN-gamma production by T cells.

Authors:  H Okamura; H Tsutsi; T Komatsu; M Yutsudo; A Hakura; T Tanimoto; K Torigoe; T Okura; Y Nukada; K Hattori
Journal:  Nature       Date:  1995-11-02       Impact factor: 49.962

3.  Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme.

Authors:  C A Ray; R A Black; S R Kronheim; T A Greenstreet; P R Sleath; G S Salvesen; D J Pickup
Journal:  Cell       Date:  1992-05-15       Impact factor: 41.582

4.  Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence.

Authors:  C Upton; J L Macen; M Schreiber; G McFadden
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

5.  T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor.

Authors:  C A Smith; T Davis; J M Wignall; W S Din; T Farrah; C Upton; G McFadden; R G Goodwin
Journal:  Biochem Biophys Res Commun       Date:  1991-04-15       Impact factor: 3.575

6.  Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits.

Authors:  K Mossman; P Nation; J Macen; M Garbutt; A Lucas; G McFadden
Journal:  Virology       Date:  1996-01-01       Impact factor: 3.616

7.  Virus-induced loss of class I MHC antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus.

Authors:  L K Boshkov; J L Macen; G McFadden
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

8.  A rabbitpox virus serpin gene controls host range by inhibiting apoptosis in restrictive cells.

Authors:  M A Brooks; A N Ali; P C Turner; R W Moyer
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

Review 9.  Lymphocyte adhesion to endothelium.

Authors:  U Dianzani; F Malavasi
Journal:  Crit Rev Immunol       Date:  1995       Impact factor: 2.214

10.  Vaccinia DNA ligase complements Saccharomyces cerevisiae cdc9, localizes in cytoplasmic factories and affects virulence and virus sensitivity to DNA damaging agents.

Authors:  S M Kerr; L H Johnston; M Odell; S A Duncan; K M Law; G L Smith
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  24 in total

Review 1.  Poxvirus immunomodulatory strategies: current perspectives.

Authors:  J B Johnston; Grant McFadden
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.

Authors:  Lisa M Sedger; Sarah R Osvath; Xiao-Ming Xu; Grace Li; Francis K-M Chan; John W Barrett; Grant McFadden
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus.

Authors:  J Bárcena; M Morales; B Vázquez; J A Boga; F Parra; J Lucientes; A Pagès-Manté; J M Sánchez-Vizcaíno; R Blasco; J M Torres
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  The inflammasome as a target of modulation by DNA viruses.

Authors:  Lisi Amsler; Daniel Malouli; Victor DeFilippis
Journal:  Future Virol       Date:  2013-04-01       Impact factor: 1.831

Review 5.  Viral serpin therapeutics from concept to clinic.

Authors:  Hao Chen; Donghang Zheng; Jennifer Davids; Mee Yong Bartee; Erbin Dai; Liying Liu; Lyubomir Petrov; Colin Macaulay; Robert Thoburn; Eric Sobel; Richard Moyer; Grant McFadden; Alexandra Lucas
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

6.  Myxoma virus Serp2 is a weak inhibitor of granzyme B and interleukin-1beta-converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus-infected cells.

Authors:  P C Turner; M C Sancho; S R Thoennes; A Caputo; R C Bleackley; R W Moyer
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 7.  Central roles of NLRs and inflammasomes in viral infection.

Authors:  Thirumala-Devi Kanneganti
Journal:  Nat Rev Immunol       Date:  2010-09-17       Impact factor: 53.106

8.  Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins.

Authors:  Jean-Luc Guerin; Jacqueline Gelfi; Severine Boullier; Maxence Delverdier; Frederique-Anne Bellanger; Stephane Bertagnoli; Ingo Drexler; Gerd Sutter; Frederique Messud-Petit
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

9.  The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responses.

Authors:  Carolina R Melo-Silva; David C Tscharke; Mario Lobigs; Aulikki Koskinen; Yik Chun Wong; R Mark Buller; Arno Müllbacher; Matthias Regner
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

10.  A virulence factor of myxoma virus colocalizes with NF-kappaB in the nucleus and interferes with inflammation.

Authors:  Christelle Camus-Bouclainville; Laurence Fiette; Sophie Bouchiha; Béatrice Pignolet; Dorian Counor; Cédric Filipe; Jacqueline Gelfi; Frédérique Messud-Petit
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.